Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Monday that it has entered into a definitive agreement to acquire Intra-Cellular Therapies Inc (Nasdaq:ITCI), a biopharmaceutical company focused on central nervous system (CNS) disorders, for USD132.00 per share in cash.
The acquisition includes CAPLYTA (lumateperone), approved for the treatment of schizophrenia and bipolar depression. The US Food and Drug Administration (FDA) is currently reviewing an application for CAPLYTA as an adjunctive treatment for major depressive disorder (MDD).
CAPLYTA has the potential to become a standard of care for most common depressive disorders and is expected to generate USD5bn+ in peak year sales. The deal also includes ITI-1284, a promising Phase 2 compound being studied in generalised anxiety disorder and Alzheimer's disease-related psychosis and agitation.
Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close later this year.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024